Resource Type

Journal Article 1

Year

2018 1

Keywords

AML 1

cytarabine 1

leukemia 1

venetoclax 1

Search scope:

排序： Display mode:

Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid

Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song, Delong Liu

Frontiers of Medicine 2018, Volume 12, Issue 5,   Pages 593-599 doi: 10.1007/s11684-018-0635-y

Abstract: Venetoclax, a BCL-2 inhibitor, has been approved for the treatment of relapsed and/or refractory chronicClinical trials on applying venetoclax in combination with cytarabine and other agents to treat varioushigh risk AML achieved complete response to the combined treatment regimen of low-dose cytarabine and venetoclaxFurthermore, we reviewed current clinical trials on the use of venetoclax for hematological malignancies

Keywords： venetoclax     cytarabine     AML     leukemia    

HTML PDF Collect

Title Author Date Type Operation

Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid

Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song, Delong Liu

Journal Article